Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Completed · Phase 1

Conditions studied: Unspecified Adult Solid Tumor, Protocol Specific

In brief

Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of combining bortezomib with carboplatin and etoposide in treating patients who have advanced solid tumors that have not responded to previous treatment

Key facts

Study ID

NCT00027898

Run by

National Cancer Institute (NCI)

People needed

27

Starts

2002-01-01

Last updated by the study team

2013-02-07

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed advanced solid tumor cancer for which no curativetherapy exists
• Clinically stable CNS disease is allowed provided the following criteria are met:
• No uncontrolled brain metastases or CNS involvement
• No active seizures
• On stable dose of antiseizure or steroid medication for at least 7 days before study enrollment
• Performance status - ECOG 0-2
• At least 12 weeks
• Absolute neutrophil count at least 1,500/mm\^3
• Hemoglobin at least 9 g/dL
• Platelet count at least 100,000/mm\^3
• Bilirubin no greater than 1.5 mg/dL
• AST/ALT no greater than 2.5 times upper limit of normal
• Creatinine no greater than 1.5 mg/dL
• Creatinine clearance at least 60 mL/min
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No active infection
• No other serious concurrent systemic disorders (including other malignancy)
• No prior bone marrow or peripheral blood stem cell transplantation
• No concurrent immunotherapy
• See Disease Characteristics
• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
• Prior carboplatin and/or etoposide allowed
• No more than 2 prior courses of mitomycin

Where it is running

• University of Colorado — Denver, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.